- Home
- SFWL vs MRSN Comparison
SFWL vs MRSN Comparison
Compare SFWL & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- MRSN
- Stock Information
- Founded
- SFWL 2001
- MRSN 2001
- Country
- SFWL China
- MRSN United States
- Employees
- SFWL N/A
- MRSN N/A
- Industry
- SFWL Trucking Freight/Courier Services
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- MRSN Health Care
- Exchange
- SFWL Nasdaq
- MRSN Nasdaq
- Market Cap
- SFWL 80.8M
- MRSN 71.9M
- IPO Year
- SFWL 2023
- MRSN 2017
- Fundamental
- Price
- SFWL $1.00
- MRSN $0.53
- Analyst Decision
- SFWL
- MRSN Buy
- Analyst Count
- SFWL 0
- MRSN 7
- Target Price
- SFWL N/A
- MRSN $6.00
- AVG Volume (30 Days)
- SFWL 21.1K
- MRSN 5.4M
- Earning Date
- SFWL 03-27-2025
- MRSN 03-07-2025
- Dividend Yield
- SFWL N/A
- MRSN N/A
- EPS Growth
- SFWL N/A
- MRSN N/A
- EPS
- SFWL 0.11
- MRSN N/A
- Revenue
- SFWL $446,281,000.00
- MRSN $34,837,000.00
- Revenue This Year
- SFWL N/A
- MRSN N/A
- Revenue Next Year
- SFWL N/A
- MRSN N/A
- P/E Ratio
- SFWL $9.29
- MRSN N/A
- Revenue Growth
- SFWL 14.80
- MRSN N/A
- 52 Week Low
- SFWL $0.81
- MRSN $0.49
- 52 Week High
- SFWL $2.23
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- SFWL 44.19
- MRSN 32.86
- Support Level
- SFWL $0.98
- MRSN $0.56
- Resistance Level
- SFWL $1.04
- MRSN $0.82
- Average True Range (ATR)
- SFWL 0.04
- MRSN 0.07
- MACD
- SFWL 0.00
- MRSN 0.03
- Stochastic Oscillator
- SFWL 30.70
- MRSN 8.39
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. The company offers contract logistics services comprising planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The integrated logistics solution services of the company are comprised of three segments: B2B freight transportation; cloud storage; and value-added services.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.